Grunthenthal acquires Thar Pharmaceuticals and with it T 121 (oral zoledronic acid) for CRPS

Gr�nenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, has announced its recent acquisition of Thar Pharmaceuticals, a US-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology Enhance development platform. With this acquisition, Gr�nenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical�s lead development candidate, T 121. T 121 is a novel, Phase III-ready, composition-of-matter patented oral zoledronic acid drug product. It has received orphan drug designation by the FDA. T 121 complements and broadens Gr�nenthal's portfolio for CRPS (Complex Regional Pain Syndrome) which includes IV neridronate that is currently in phase III clinical development. Gr�nenthal will conduct clinical phase III development to demonstrate efficacy and safety of T 121 for the treatment of patients with CRPS. Preclinical and pilot clinical evidence suggest that zoledronic acid could significantly reduce pain and other debilitating symptoms of CRPS.